Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153578 · ClinicalTrials.gov registry record
Time to Lose the Weight? Comparison of Weight-based and Non-weight-based Vasopressors for Septic Shock
A clinical trial of Septic Shock and Weight, Body, sponsored by Methodist Health System.
- Completed
- Registry status
- 945
- Enrollment target
- 1
- Study location
NCT04153578: Completed study of Septic Shock and Weight, Body, sponsored by Methodist Health System.
NCT04153578 is a study of Septic Shock and Weight, Body that has completed, run by Methodist Health System. The registered enrollment target is 945 participants, below the 5,020-participant average among 24 other Septic Shock trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04153578, a study of Septic Shock and Weight, Body, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 945 participants
- Enrollment target
- 1
- Study location
Study Summary
At present, there is conflicting evidence regarding outcomes in patients with septic shock receiving weight-based vasopressor (WBVP) versus non-weight-based vasopressor (NWBVP) dosing strategies. At MCMC, a weight-based strategy is in place whereas MDMC, MMMC and MRMC currently utilize a non-weight-based dosing strategy. Obese patients (BMI \> 30) receiving either strategy may potentially be receiving substantially more or less vasopressor exposure compared to their non-obese (BMI \< 30) counterparts. Determining total vasopressor exposure and assessing clinical outcomes would benefit our institution and others by providing optimal vasopressor dosing strategies in obese and non-obese patients. There is a difference in clinical outcomes between patients receiving weight-based and non-weight-based vasopressor dosing strategies. There is a difference in total vasopressor exposure between obese and non-obese patients utilizing WBVP and NWBVP strategies.
Primary Outcome
Total 48-hour vasopressor exposure (norepinephrine (NE) equivalents, mg)
Conditions Studied
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 945 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2020-06-22 |
What the finished NCT04153578 record still lists
NCT04153578 is an observational study that tracks outcomes without assigning an intervention. The registered 945 participants enrollment target is mid-sized for trials with a published cap, below the 5,020-participant average among 24 other Septic Shock trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Septic Shock appearing as the primary indexed condition, and to 0 interventions.
NCT04153578 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04153578 about?
NCT04153578 is a clinical study titled "Time to Lose the Weight? Comparison of Weight-based and Non-weight-based Vasopressors for Septic Shock". At present, there is conflicting evidence regarding outcomes in patients with septic shock receiving weight-based vasopressor (WBVP) versus non-weight-based vasopressor (NWBVP) dosing strategies. At MCMC, a weight-based strategy is in place whereas MDMC, MMMC and MRMC currently utilize a non-weight-...
What is the current status of trial NCT04153578?
This trial is currently completed. The enrollment target is 945 participants. The study started on 2019-11-04. Estimated completion is 2020-06-22.
What conditions does trial NCT04153578 study?
This clinical trial studies the following conditions: Septic Shock, Weight, Body.
Who is sponsoring clinical trial NCT04153578?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04153578 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04153578's enrollment target sits among peer trials
945 7th of 24 higher than 18 of 24 other Septic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
Assessment for Implementation Methods in Sepsis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI